AbCellera settles Bruker patent litigation; $36M upfront plus ongoing royalties

AbCellera Biologics Inc.

Bruker to pay AbCellera $36 million upfront as part of global patent settlement.
Bruker will also pay future royalties on worldwide sales of its Beacon Optofluidic platform.
Settlement resolves all patent litigation between AbCellera and Bruker globally.
No other terms of the license agreement were disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.